Fludarabine: all 769 studies that test it
Page 1 of 8. Open to participants first (148), then studies with results posted, then the rest; newest registration first within each.
- A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02)RecruitingNCT07830342Phase 1
- Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic SyndromeNot yet recruitingNCT07819396Phase 2
- Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic LymphomaNot yet recruitingNCT07758673Phase 1
- Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell TransplantNot yet recruitingNCT07634536Phase 2
- EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCCRecruitingNCT07617805Phase 1/2
- Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic CarcinomaRecruitingNCT07598955Phase 1/2
- FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AMLNot yet recruitingNCT07598110Phase 2
- Haplo-Cord HSCT for AML/MDSRecruitingNCT07588360Not applicable
- BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 MutationNot yet recruitingNCT07583303Phase 1
- Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic SyndromeRecruitingNCT07582172Phase 2
- Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors.RecruitingNCT07570563Phase 1/2
- Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
- TBF Conditioning Regimen for Haploidentical Stem Cell Transplantation in Elderly AML Patients in First Complete RemissionNot yet recruitingNCT07563920Not applicable
- Dual-target CLDN18.2/HER2 CAR-NK Cells for Advanced Gastric/GEJ CancerRecruitingNCT07551362Phase 1/2
- Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaRecruitingNCT07551349Phase 1/2
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07551336Phase 1
- Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood CancersNot yet recruitingNCT07524530Phase 2
- SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory LupusRecruitingNCT07523542Phase 1/2
- Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid TumorsRecruitingNCT07523529Phase 1/2
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological DiseasesRecruitingNCT07493538Phase 2
- Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial CarcinomaRecruitingNCT07492628Phase 1
- Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade GliomaRecruitingNCT07480941Phase 1
- The Safety and Efficacy of the Regimen of Thiotepa + Fludarabine +Granulocyte Colony-Stimulating Factor+ Cytarabine + Busulfan in Single Unrelated Umbilical Cord Blood TransplantationNot yet recruitingNCT07441967Phase 2
- Evaluating Efficacy of B7-H3-CAR T Cells Administered at the End of Upfront Map Chemotherapy in Patients With Newly Diagnosed High-Risk OsteosarcomaRecruitingNCT07428993Phase 2
- CAR BCMA-70 CAR-T Cells for the Treatment of High-risk Plasma Cell NeoplasmsRecruitingNCT07416682Early Phase 1
- Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")RecruitingNCT07411599Phase 1/2
- Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid TumorsRecruitingNCT07410494Phase 1/2
- TCR-T Cell Therapy for KRAS Mutation in Advanced Solid TumorsNot yet recruitingNCT07342738Early Phase 1
- TIL Therapy in cSCC and MCCRecruitingNCT07288073Phase 2
- CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and LymphomaRecruitingNCT07257419Phase 1
- TC-D101 Cell Therapy for Patients With DLL3-Positive SCLCRecruitingNCT07246304Early Phase 1
- Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid LeukemiaRecruitingNCT07228273Phase 2
- A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic LeukemiaRecruitingNCT07223021Phase 3
- Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme MalignanciesRecruitingNCT07214688Phase 2
- A Study to Evaluate Efficacy and Safety of Ciltacabtagene AutoleucelRecruitingNCT07149857Phase 2
- A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed/Refractory Autoimmune DiseasesRecruitingNCT07144462Early Phase 1
- Allogeneic CD7 CAR γδ T Cells Therapy Recurrent/Refractory LeukemiaNot yet recruitingNCT07120607Phase 1
- A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune DiseasesRecruitingNCT07115745Phase 1
- HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01)RecruitingNCT07105176Phase 1
- Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)RecruitingNCT07101432Phase 1
- GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsRecruitingNCT07087002Phase 1
- Reduced Intensity Conditioning for MDSNot yet recruitingNCT07085156Phase 2
- A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseaseRecruitingNCT07085104Phase 1
- Efficacy and Safety of UCBT With TMI -Based Conditioning Regimen for Adults With Refractory/Relapsed Aplastic AnemiaNot yet recruitingNCT07078721Phase 2
- A Phase 1 Study of FIT-CD19-CAR-T Cells in R/R B-ALLRecruitingNCT07066397Phase 1
- UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AMLRecruitingNCT07059975Early Phase 1
- Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid CancerRecruitingNCT07046078Phase 2
- Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsRecruitingNCT07010523Not applicable
- MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal TumorsRecruitingNCT07004647Not applicable
- CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic DifferentiationNot yet recruitingNCT06986434Early Phase 1
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)Not yet recruitingNCT06954987Phase 2
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
- Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid LeukemiaRecruitingNCT06871410Phase 1
- Thiotepa Combined With Busulfan and Fludarabine Conditioning Regimen for Haploidentical Hematopoietic Stem Cell Transplantation in Elderly Patients With High-Risk Acute Myeloid LeukemiaRecruitingNCT06869265Phase 2
- FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingNCT06865664Phase 1
- CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive LeukemiaRecruitingNCT06847269Phase 2
- Novel Allogenic CD19-targeting CAR-γδT Cell Therapy (QH103E) in r/r NHLRecruitingNCT06838832Phase 1/2
- Human Leukocyte Antigen (HLA) Mismatched Unrelated Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06809712Phase 1
- Human Leukocyte Antigen (HLA) Mismatched Related Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06809699Phase 1
- Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell TransplantationRecruitingNCT06807606Phase 2
- Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)RecruitingNCT06802315Phase 2
- CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic LeukemiaRecruitingNCT06777979Phase 1
- A Study of CAR T-Cells in Relapsed/Refractory Hematologic MalignancyRecruitingNCT06756321Early Phase 1
- Allogeneic CD19-targeted CAR-γδT Cell Infusion Therapy in Relapsed/Refractory B Cell Acute Lymphoblastic LeukemiaRecruitingNCT06696833Early Phase 1
- Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)RecruitingNCT06660420Phase 1
- Clinical Study of SN301A Injection in the Treatment of Hepatocellular CarcinomaRecruitingNCT06652243Early Phase 1
- CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular CarcinomaNot yet recruitingNCT06641453Phase 1/2
- Anti-CD19-CAR-T Cells in Subjects with Relapsed/Refractory B Cell MalignanciesRecruitingNCT06532630Early Phase 1
- Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLRecruitingNCT06500273Phase 2
- Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Myeloid MalignanciesRecruitingNCT06383572Phase 1/2
- Ma-Spore ALL 2020 StudyRecruitingNCT06336395Phase 2
- CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological MalignanciesRecruitingNCT06326463Phase 1
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic SyndromeRecruitingNCT06287944Phase 1
- Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning for MDSRecruitingNCT06247917Phase 2
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyRecruitingNCT06247787Phase 1
- Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPCRecruitingNCT06193486Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT06121570Phase 1
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT06121557Phase 1
- A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid TumorsRecruitingNCT06101082Phase 1
- Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)RecruitingNCT06066424Phase 1
- Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid TumorsRecruitingNCT06047977Phase 1
- T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon CancerRecruitingNCT06043713Phase 1
- Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell TransplantationRecruitingNCT06028828Phase 2
- Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid MalignanciesRecruitingNCT05991908Phase 3
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast CancerRecruitingNCT05981014Phase 1/2
- Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast CancerRecruitingNCT05981001Phase 1/2
- CAR T-cell Therapy in Patients With Renal DysfunctionRecruitingNCT05909059Phase 2
- Delayed Tolerance Through Mixed ChimerismRecruitingNCT05900401Phase 1/2
- AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes in Patients With Multiple SclerosisRecruitingNCT05832515Phase 1
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory ConditionRecruitingNCT05787574Phase 2
- Allogeneic γ9δ2 T Cells Treatment of Recurrent Hematologic TumorsRecruitingNCT05755854Phase 1
- A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)RecruitingNCT05736419Phase 2
- MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme MalignanciesRecruitingNCT05735717Phase 2
- CD19-targeted CAR T Cells for Patients With Relapsed or Refractory in B-cell Acute Lymphoblastic LeukemiaRecruitingNCT05727683Phase 1
- Clinical Trial Using CAR- T Cells for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid MalignanciesRecruitingNCT05705570Phase 1
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLLRecruitingNCT05702853Phase 1/2
- Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid TumorsRecruitingNCT05693844Phase 1/2
- HER2 Targeted HypoSti.CAR-T Cells in HER2 Positive Advanced Solid TumorsRecruitingNCT05681650Phase 1/2